logo
episode-header-image
Jun 2021
11m 52s

FDA Approves Aducanumab — A Controversia...

NPR
About this episode
The FDA has approved a new drug for Alzheimer's. But a lot of experts are skeptical about whether the drug works. Rhitu Chatterjee talks with science correspondent Jon Hamilton about the controversial drug aducanumab and why the U.S. Food and Drug Administration approved it.

For more of Jon's reporting, read "For Those Facing Alzheimer's, A Controversial Drug Offers Hope."

You can email Short Wave at ShortWave@NPR.org.

See pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.

NPR Privacy Policy
Up next
Yesterday
Shooting stars are just pea-sized rocks... and other space wonders
Ahead of the peak of the Perseid meteor shower, we're re-airing our first episode with host Regina G. Barber. In it, Regina and planetary scientist Melissa Rice explore all things shooting stars. They talk about the different types, where they come from and what they actually are ... Show More
11m 40s
Aug 4
More food and money, less disease: Senegal's surprising eco-experiment
In Senegal, rice farmers are trying to kill three birds with one stone – er, fish. Rice and fish are already a natural combination; they’re even the main ingredients of thieboudienne, the delicious national dish. But could that combination also reduce a debilitating disease, boos ... Show More
13m 30s
Aug 3
The new era of AI-powered cybercrime
Hacking has been on the rise around the world. In 2025, the FBI’s Internet Crime Complaint Center received over 1 million complaints of cybercrime, a record high in the US. Hackers are always getting more creative, and now they have a new tool at their disposal: AI. Interested in ... Show More
12m 28s
Recommended Episodes
Jul 2021
'Some Hope Is Better Than Having No Hope'
<p>When the F.D.A. approved the drug Aduhelm, the first Alzheimer’s treatment to receive the agency’s endorsement in almost two decades, it gave hope to many.</p><p>But the decision was contentious; some experts say there’s not enough evidence that the treatment can address cogni ... Show More
36m 59s
Aug 2021
Controversial new Alzheimer's drug in the spotlight
After decades without progress, this June a new treatment was approved by the US Food and Drugs Administration - Biogen's Aduhelm. Ivana Davidovic looks into why this process has been so controversial that is now under investigation by a federal watchdog.Aaron Kesselheim, a Harva ... Show More
18m 21s
Jun 2021
Alzheimer’s drug has experts divided; rising ICE use in Australia; the disappointing results of a study aimed at improving ovarian cancer survival rates
This week, the first of a new series on substance use and what you need to know about ICE - crystal meth. Does early diagnosis of ovarian cancer through screening make a difference to survival rates? And the search for an Alzheimer's disease treatment is as controversial as ever. ... Show More
35m 10s
Apr 2023
Audio long read: Conquering Alzheimer’s — a look at the therapies of the future
Last year, researchers announced that the Alzheimer’s drug lecanemab lowered the amount of amyloid protein plaques associated with the disease in the brains of participants in a clinical trial, and slowed their cognitive decline.Now, researchers are looking to drug combinations, ... Show More
17m 31s
Sep 2022
An Alzheimer's uproar
This past July, a bombshell report in Science magazine suggested that a key Alzheimer’s study might have contained manipulated evidence. What does this mean for over a decade's worth of research? And where does the field go from here? For more, go to http://vox.com/unexplainable ... Show More
36m 40s
Jul 2023
AAN President Elect Testified Before House Subcommittee on New Alzheimer Treatment
Dr. Stacey Clardy talks with Dr. Natalia Rost about her experience speaking before the House of Representatives on the approval of lecanemab for the treatment of early Alzheimer disease. Visit NPUb.org/Podcast for associated article links. This episode was sponsored by the ExTING ... Show More
14m 27s